Canary Oncoceutics

What Canary Oncoceutics does

Canary Oncoceutics is a privately held precision oncology diagnostics company that provides next-generation sequencing (NGS)-based genomic profiling and AI-assisted interpretation for cancer treatment selection, recurrence monitoring, and hereditary risk assessment. Its core wet-lab stack combines Illumina sequencing platforms with Twist Biosciences DNA synthesis and Agilent instrumentation, and the company markets a six-test portfolio: Canary Acuity (1,091-gene comprehensive genomic profiling, CLIA-certified and CAP-accredited for solid and liquid tumors), Canary Pulse (468-gene liquid biopsy / ctDNA), Canary Focus (focused panel), Canary Stat (focused liquid biopsy), Canary HRD (homologous recombination deficiency), and Canary Stat Heredit (93-gene hereditary panel), plus CanaryScan Prostate, an AI-powered urine-based early-detection test. Operations are run from a Phoenix, Arizona headquarters and an Indian regional entity, Canary Oncoceutics India Private Limited, in Noida, with active service coverage in the US, India, and the United Arab Emirates.

Name

Canary Oncoceutics

Legal name

Canary Oncoceutics India Private Limited

Website

https://canaryonco.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Canary Oncoceutics is a privately held CLIA-certified, CAP-accredited precision oncology diagnostics company offering NGS-based comprehensive genomic profiling, liquid biopsy, hereditary, and AI-powered screening tests to hospitals, oncologists, and biopharma partners across the US, India, and the UAE.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Genomic profiling
• Precision oncology
• Liquid biopsy
• Companion diagnostics
• Cancer diagnostics

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Genomic Testing Services: Direct B2B genomic testing services provided to healthcare providers, hospitals, and cancer centers. Tests are ordered by physicians for their patients and results are delivered directly to ordering providers.
2. Companion Diagnostic (CDx) Services: Companion diagnostic development and testing services for biopharma partners to support drug development and personalized treatment matching.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels10 records

Core offering

Canary Oncoceutics is a precision oncology diagnostics company that provides CLIA-certified and CAP-accredited next-generation sequencing based genomic profiling tests for cancer patients. The portfolio includes comprehensive gene profiling (1091 genes), liquid biopsy ctDNA analysis, focused gene panels, HRD panels, and hereditary cancer risk panels. Tests are ordered by physicians and processed at the company's laboratories, with a 14-day standard turnaround time.

Product overview

Canary Oncoceutics offers a portfolio of six advanced genomic testing services for precision oncology diagnostics. The core offerings include Canary Acuity (comprehensive genomic profiling analyzing 1091 genes), Canary Pulse (liquid biopsy for ctDNA analysis covering 468 genes), Canary Focus (targeted gene panel for common cancers), Canary Stat (focused liquid biopsy panel), Canary HRD (homologous recombination deficiency panel), and Canary Stat Heredit (hereditary cancer risk panel with 93+ genes). All tests are CLIA-certified and CAP-accredited, leveraging next-generation sequencing technology and AI-powered analytics to provide actionable insights for personalized cancer treatment.

Differentiator

Problem solved

Functional benefit

Brands

• Canary Acuity: Comprehensive Gene Profiling (CGP) test examining 1091 genes for solid and liquid tumors, CLIA-certified and CAP-Accredited
• Canary Focus
• Canary Pulse
• Canary Stat
• Canary HRD
• Canary Stat Heredit
• CanaryScan Prostate

Products and services

• Canary Acuity CLIA-certified and CAP-accredited comprehensive genomic profiling (CGP) test analyzing 1091 cancer-associated genes for solid and liquid tumors, enabling tailored treatment strategies including targeted therapy and immunotherapy selection. Designed for oncologists and cancer specialists treating patients requiring comprehensive molecular profiling.
• Canary Pulse Liquid biopsy test analyzing 468 carefully selected cancer-related genes using peripheral blood samples (circulating tumor DNA). Enables early detection of tumor recurrence and disease progression monitoring without invasive tissue biopsy, intended for oncologists managing patients on therapy.
• Canary Focus Streamlined focused gene panel test for solid and liquid tumors that identifies relevant mutations for targeted therapies or other actionable clinical interventions at a more affordable price point. Targeted at cancer patients seeking personalized treatment recommendations or longitudinal monitoring.
• Canary Stat Focused liquid biopsy panel for genomic profiling offering diagnosis, prognosis, and targeted therapy guidance through ctDNA analysis. Designed for rapid liquid biopsy-based clinical decision support.
• Canary HRD Homologous Recombination Deficiency (HRD) gene panel providing genomic profiling for diagnosis, prognosis, and targeted therapy selection in cancers associated with HRD mutations.
• Canary Stat Heredit Focused hereditary cancer panel analyzing 93 genes plus 47 additional cancer genes, 76 pharmacogenomics (PGx) markers, and 17 intronic fusions. Identifies genetic mutations for cancer risk assessment, enabling early detection, personalized prevention, family risk evaluation, and eligibility for targeted therapies. Accepts peripheral blood, saliva, and buccal swab samples.

Quantifiable outcome

• 1091 genes analyzed - more comprehensive than competitors offering 300-500 genes
• +2 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• Twist BiosciencescoreTechnology or IntegrationStrategic partnership for DNA synthesis and genomic technologies supporting Canary's comprehensive genomic profiling tests.
• AgilentcoreTechnology or IntegrationTechnology partnership for genomic analysis solutions and instruments supporting laboratory operations.
• Genetics Institute of AmericacoreStrategic or Co-development PartnerCollaboration in genetic testing services and expertise sharing for advanced cancer diagnostics.
• IlluminacoreTechnology or IntegrationPartnership for next-generation sequencing technology and platforms powering Canary's genomic profiling tests.
• CamebicoreTechnology or IntegrationTechnology partnership for genomic analysis and bioinformatics solutions.

Scale indicators5 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• Guardant Health: Guardant Health is a leader in liquid biopsy and MRD oncology testing (Guardant360, Reveal), directly comparable to Canary Pulse and the MRD/monitoring use cases of the portfolio.
• Personalis: Personalis provides comprehensive genomic profiling (NeXT Personal) for oncology and biopharma customers — a direct peer in the CGP and immuno-oncology biomarker space.
• Caris Life Sciences: Caris provides comprehensive molecular profiling (MI Profile), liquid biopsy, and AI analytics for oncology — comparable to Canary's full test portfolio across tissue and liquid biopsy.
• Natera: Natera operates oncology-focused molecular testing (Signatera for MRD and related assays) that overlaps with Canary's liquid biopsy and recurrence-monitoring offerings.
• Foundation Medicine: Foundation Medicine (a Roche company) is the leading US provider of comprehensive genomic profiling (FoundationOne CDx) and is the canonical direct peer for Canary's CGP/liquid biopsy oncology diagnostics business.
• Tempus Labs: Tempus offers NGS-based oncology profiling, AI-driven analytics, and biopharma data services — a near-direct parallel to Canary Acuity and the AI/bioinformatics capability set.
• NeoGenomics: NeoGenomics operates oncology-focused clinical labs offering CGP, liquid biopsy, and hematology testing services, comparable to Canary's hospital- and oncologist-facing diagnostic business.

Broad incumbents

• Exact Sciences: Exact Sciences is a broader cancer diagnostics incumbent (Cologuard, Oncotype, Thrive) that overlaps with Canary's hereditary and oncology testing categories from a larger, multi-product platform.
• Myriad Genetics:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/canaryonco
• YouTubeyoutube.com/@canaryoncoofficial
• Facebookfacebook.com/canaryonco
• LinkedInlinkedin.com/company/canaryonco
• Instagraminstagram.com/canaryonco

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canary Oncoceutics